BlueCrest Capital Management’s Reviva Pharmaceuticals Warrants RVPHW Stock Holding History

BlueCrest Capital Management’s Portfolio RVPHW Stock Details RVPHW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,251,250	Closed	-$239K	–	196
2022 Q3	$239K	Buy	1,251,250 +16,250	+1%	+$3.54K	0.01%	157
2022 Q2	$222K	Buy	1,235,000 +14,400	+1%	+$2.91K	0.01%	162
2022 Q1	$333K	Hold	1,220,600	–	–	0.01%	227
2021 Q4	$427K	Hold	1,220,600	–	–	0.01%	256
2021 Q3	$488K	Hold	1,220,600	–	–	0.01%	292
2021 Q2	$620K	Hold	1,220,600	–	–	0.01%	413
2021 Q1	$561K	Hold	1,220,600	–	–	0.01%	565
2020 Q4	$824K	Hold	1,220,600	–	–	0.02%	302
2020 Q3	$623K	Hold	1,220,600	–	–	0.02%	233
2020 Q2	$574K	Buy	1,220,600 +400,000	+49%	+$93.7K	0.03%	180
2020 Q1	$74K	Buy	820,600 +216,100	+36%	+$32.4K	0.01%	191
2019 Q4	$151K	Hold	604,500	–	–	0.01%	352
2019 Q3	$151K	Hold	604,500	–	–	0.01%	513
2019 Q2	$127K	Hold	604,500	–	–	0.01%	368
2019 Q1	$97K	Buy	604,500 +254,500	+73%	+$50.4K	﹤0.01%	1081
2018 Q4	$116K	Buy	+350,000	New	+$112K	0.01%	744

Other funds holding RVPHW

Arena Investors Purchase, New York $12.5M AUM 0.27% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

NewSquare Capital Newtown Square, Pennsylvania $1.15B AUM 24.78% 1-Year Est. Return

BlueCrest Capital Management's RVPHW Position: Q4 2022 in Review

BlueCrest Capital Management sold out of Reviva Pharmaceuticals Warrants (RVPHW) in Q4 2022, closing a stake of 1,251,250 shares — an estimated $239K sold.

BlueCrest Capital Management first reported a position in RVPHW in Q4 2018 and held it in 16 quarters. The position peaked at $824K in Q4 2020. 5 funds tracked by Wall St. Rank hold RVPHW as of Q4 2022.

BlueCrest Capital Management reported no remaining Reviva Pharmaceuticals Warrants position as of Q4 2022 after selling out during the quarter.
BlueCrest Capital Management sold 1,251,250 Reviva Pharmaceuticals Warrants shares in Q4 2022, an estimated $239K.
BlueCrest Capital Management first reported a position in Reviva Pharmaceuticals Warrants in Q4 2018 and held it in 16 quarters.
BlueCrest Capital Management's Reviva Pharmaceuticals Warrants position peaked at $824K in Q4 2020.
5 funds tracked by Wall St. Rank held Reviva Pharmaceuticals Warrants as of Q4 2022.

Based on BlueCrest Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.